Robert Manges

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

Herbert I. Hurwitz, Nikhil Uppal, Stephanie A. Wagner et al. · Journal of Clinical Oncology · 2015 · 279 citations · Full text

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Philippe Rougier, Hanno Riess, Robert Manges et al. · European Journal of Cancer · 2013 · 179 citations

Oncology, Pancreatic Cancer, Pharmacology +6

A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

Peter M. Voorhees, Robert Manges, Pieter Sonneveld et al. · British Journal of Haematology · 2013 · 142 citations

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

Jesús G. Berdeja, Sundar Jagannath, Jeffrey A. Zonder et al. · Clinical Lymphoma Myeloma & Leukemia · 2015 · 69 citations · Full text